[First issue] Inno Lake Pharmaceuticals completed 300 million yuan Pre-A round of financing, focusing on building the world's first or best-in-class new drug research and development product line

Artery Network was informed for the first time that Inno Lake Pharmaceuticals (Hangzhou) Co.

Inno Lake Pharmaceutical (Hangzhou) Co.

About WuXi Biologics

WuXi Biologics (stock code: 2269.
HK), as a Hong Kong listed company, is the world's leading open and integrated biopharmaceutical capabilities and technology empowerment platform.
The company provides a full range of end-to-end R&D services for global biopharmaceutical companies and biotechnology companies to help anyone and any company discover, develop and produce biopharmaceuticals, realize the whole process from concept to commercial production, and accelerate global biopharmaceutical research and development Process, reduce research and development costs, and benefit patients.
As of December 31, 2020, there are 334 comprehensive projects developed on WuXi Biologics platform, including 169 in pre-clinical research stage, 135 in early clinical phase (phase I, phase II), and 28 in late clinical phase.
(Phase III) and 2 are in the commercial production stage.
It is estimated that by 2024, the company's planned biopharmaceutical production bases in China, Ireland, the United States, Germany and Singapore will have a combined production capacity of 430,000 liters, which will effectively ensure that the company provides customers with global quality through a sound and strong global supply chain network.
Standard biological medicine.

About Hangzhou Huaan Jingyin Investment

Huaan Jingyin was established in February 2016.
It is a professional fund focusing on investment in the life sciences field, covering: life science basic research services, early detection, diagnosis, clinical research services, biopharmaceuticals, regenerative medicine, new materials for drug delivery, Health commercial insurance services, etc.

About CDH Investment Innovation and Growth Fund

CDH Investment was established in 2002 and is one of the most influential alternative asset management institutions in China.
As of 2020, the scale of funds under management exceeds RMB 160 billion.
CDH Investments has six business segments: private equity investment, innovation and growth, securities investment, real estate investment, mezzanine investment, and wealth management.
CDH VGC (Innovation and Growth Fund) focuses on investment in healthcare, TMT and innovative growth opportunities with Chinese characteristics.
CDH Innovation and Growth Fund is managed by a professional investment team with rich experience and distinctive characteristics, committed to promoting the innovation and development of outstanding companies in the growth period.
Based on CDH Investment’s outstanding investment performance in the fields of healthcare and growth, and CDH’s investment focus in the TMT field, CDH Innovation and Growth Fund has established its own unique investment strategy and platform advantages, and relying on its investment team Abundant investment experience, professional judgment and operation management experience have comprehensively enhanced the value of the invested enterprise.

About Huagai Capital

Huagai Capital was established in 2012.
It is a private equity investment institution co-founded by a group of professionals from well-known domestic and foreign investment institutions in the industry.
With the vision of "becoming the most trusted capital partner for entrepreneurs and investors", the company focuses on private equity investment in the three major areas of healthcare, TMT, and digital innovation, and is committed to promoting the growth of small and medium-sized enterprises as industry leaders.
At present, the company's assets under management are about RMB 20 billion.